Firefly Neuroscience (NASDAQ:AIFF) Posts Quarterly Earnings Results

Firefly Neuroscience (NASDAQ:AIFF) issued its quarterly earnings results on Monday. The company reported ($0.10) EPS for the quarter, FiscalAI reports. Firefly Neuroscience had a negative return on equity of 94.68% and a negative net margin of 565.40%.The company had revenue of $0.51 million during the quarter.

Firefly Neuroscience Trading Down 4.2%

Firefly Neuroscience stock opened at $1.14 on Wednesday. Firefly Neuroscience has a 12 month low of $0.62 and a 12 month high of $3.63. The stock has a fifty day simple moving average of $1.28 and a two-hundred day simple moving average of $1.46. The firm has a market cap of $17.79 million, a price-to-earnings ratio of -1.81 and a beta of 0.57.

Wall Street Analysts Forecast Growth

AIFF has been the subject of several analyst reports. Wall Street Zen upgraded Firefly Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings raised shares of Firefly Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Investors Weigh In On Firefly Neuroscience

Several institutional investors have recently modified their holdings of AIFF. Geode Capital Management LLC lifted its stake in Firefly Neuroscience by 92.9% during the 2nd quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock valued at $341,000 after acquiring an additional 58,067 shares during the period. Jane Street Group LLC bought a new stake in shares of Firefly Neuroscience in the fourth quarter worth approximately $53,000. BlackRock Inc. purchased a new position in shares of Firefly Neuroscience during the second quarter valued at approximately $226,000. Finally, Vanguard Group Inc. raised its holdings in shares of Firefly Neuroscience by 393.3% during the third quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock valued at $1,464,000 after purchasing an additional 401,085 shares during the last quarter. 4.96% of the stock is owned by hedge funds and other institutional investors.

Firefly Neuroscience Company Profile

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.